GET DAILY SIGNALSAllarity Therapeutics (ALLR): Assessing the Path to the $11 Analyst Target
Key Takeaways
- The $11 target is the most recent 12-month price objective from Ascendiant Capital, the only firm currently publishing an ALLR price target; it is not a multi-analyst consensus.
- With the stock near $0.95, reaching $11 would require upside of roughly 1,060% — a very large move.
- The single covering analyst's target has been raised repeatedly over time, from $9.00 (mid-2025) to $11.00 (September 2026), reflecting a steadily more constructive view.
- Support rests on stenoparib's Fast Track designation and early Phase 2 progress, while the chief risks are cash runway, trial outcomes, and heavy dilution typical of micro-cap biotechs.
- Because only one firm covers the name, there is no meaningful "analyst consensus" to average, so the target should be treated as a single, high-risk research view.
- You can explore Major News, Today's Price Move, the Forecast, and Earnings for deeper context on ALLR.
- For automated trade ideas, browse Trending AI Robots to monitor changing conditions across thousands of stocks and ETFs.
How the $11 Target Was Established
Because ALLR lacks a meaningful pool of independent analyst targets, the $11 figure is a fallback drawn from identifiable public discussion rather than a calculated consensus. Ascendiant Capital — the sole broker publishing a current target — initiated coverage with a Buy and a $9.00 target in July 2025, then raised it to $9.50 by December 2025, to $10.25 by mid-2026, and most recently to $11.00 in September 2026. The single-analyst mean and range are therefore identical ($11.00), and the implied upside reflects a binary, speculative view of a pre-revenue biotech whose value hinges almost entirely on clinical success. This is not an "average analyst price target" in the usual sense, and investors should weigh it accordingly. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares recently trading near $0.95 and a 52-week range of roughly $0.77 to $1.84, ALLR sits in the lower portion of its range after a prolonged slide from earlier highs. Reaching $11 would require a gain of about 1,060% — a very large move by any standard, and one that would demand a decisive positive clinical catalyst rather than gradual appreciation. The company is pre-revenue, reported trailing EPS of roughly -$0.79, and carries a market capitalization of only about $15 million. The plausible path to a materially higher valuation runs through successful Phase 2 data for stenoparib, regulatory engagement, and eventually a financing or partnership that extends its runway without excessive dilution.
What Could Support a Move Toward the Target
- The U.S. Food and Drug Administration (FDA) granted Fast Track designation to stenoparib for ovarian cancer, which can enable more frequent regulatory communication and a faster review if data are positive.
- Enrollment in the Phase 2 ovarian cancer trial began in 2025, and management has highlighted expansion into small cell lung cancer and a companion-diagnostic (stenoparib-DRP) strategy.
- Recent quarterly losses have come in narrower than consensus estimates, and the covering analyst has raised both estimates and the target on several occasions.
- A differentiated dual PARP/WNT mechanism could support a compelling narrative if it demonstrates safety and efficacy versus approved PARP inhibitors.
What Could Prevent the Target From Being Reached
- As a clinical-stage company, ALLR faces binary trial risk; disappointing Phase 2 efficacy or safety data would likely invalidate the current target.
- Cash runway is a persistent concern for micro-cap biotechs. The company reported roughly $17.8 million in cash as of mid-2025, and further equity raises could dilute existing shareholders substantially.
- With a sub-$1 share price and a ~$15 million market cap, the stock is exposed to high volatility, wide spreads, and potential Nasdaq listing-compliance pressure.
- A single-firm target on a pre-revenue asset carries little independent verification and should not be read as a forecast of near-term price action.
Technical Levels and Market Structure
Technically, ALLR has established a durable support zone near its 52-week low around $0.77, while the $1.00 round-number level and the prior 52-week high near $1.84 mark the next meaningful resistance areas. Above $1.84 there is little recent trading history, meaning any advance toward $11 would be driven by fundamentals and sentiment rather than prior price structure. The enormous distance between current price and target underscores the absence of a realistic near-term technical roadmap. From what I see, monitoring these levels with tools like Tickeron’s AI Pattern Search Engine can provide additional perspective on potential breakouts.
Time Horizon and What Investors Should Monitor
The $11 target is a 12-month research horizon, consistent with typical sell-side price targets, though a single firm's view on a clinical-stage asset carries wide uncertainty. Investors should monitor Phase 2 stenoparib data readouts, FDA interactions under the Fast Track designation, quarterly cash balances and any financing or partnership announcements, and any revision to the covering analyst's estimates. Changes to trial timelines or endpoints would be the most consequential signals for whether the target's implied upside remains plausible. I'm watching this closely as new clinical updates emerge.
Exploring AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a highly volatile, thinly covered name like ALLR, such tools can help traders spot changing trends, monitor positions, and screen for opportunities more efficiently than manual review. In my view, integrating these signals has helped refine my approach to names with limited coverage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
ALLR's Stochastic Oscillator is staying in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on ALLR as a result. In 55 of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for ALLR just turned positive on October 21, 2026. Looking at past instances where ALLR's MACD turned positive, the stock continued to rise in 24 of 31 cases over the following month. The odds of a continued upward trend are 77%.
Following a +29.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLR advanced for three days, in 144 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 48 of 61 cases where ALLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALLR moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 14 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
ALLR moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ALLR moved below the 200-day moving average on October 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALLR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. ALLR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.361) is normal, around the industry mean (3.498). P/E Ratio (-1.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement